ViiV Healthcare, a global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, Wednesday announced that APRETUDE ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi ...

Quebec is the first province to publicly cover costs of long-acting injectable HIV prevention medication Apretude. Experts ...

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...

Latonia Wilkins knows she needs to be on PrEP due to her non-monogamous lifestyle. But the 52-year-old Atlanta mother has ...

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company ...

Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva ...

The drug is being jointly developed and commercialised through a partnership between Lundbeck and Otsuka. Credit: Longfin Media/Shutterstock. The European Commission (EC) has approved Otsuka ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for ...